Comparative Pharmacology
Head-to-head clinical analysis: LUVOX CR versus ZOLOFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUVOX CR versus ZOLOFT.
LUVOX CR vs ZOLOFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
100-300 mg orally once daily at bedtime
50 mg orally once daily, increased by 50 mg increments at 1-week intervals up to 200 mg/day for depression, OCD, panic disorder, PTSD, PMDD, social anxiety disorder.
None Documented
None Documented
The terminal elimination half-life is approximately 15-20 hours after single doses and 17-26 hours after multiple doses. This supports once-daily dosing, with steady-state achieved within 1-2 weeks.
26 hours (terminal elimination half-life); steady state achieved in ~1 week; metabolite desmethylsertraline half-life 66 hours.
Approximately 94% of a dose is excreted in urine, with less than 4% as unchanged drug. The remainder is eliminated in feces. Renal excretion of metabolites accounts for the majority of elimination.
Renal: <0.5% unchanged; extensive hepatic metabolism; metabolites excreted renally and fecally.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant